Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Common Equity (2016 - 2025)

Historic Common Equity for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $920.2 million.

  • Catalyst Pharmaceuticals' Common Equity rose 3923.25% to $920.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $920.2 million, marking a year-over-year increase of 3923.25%. This contributed to the annual value of $727.6 million for FY2024, which is 8759.16% up from last year.
  • Catalyst Pharmaceuticals' Common Equity amounted to $920.2 million in Q3 2025, which was up 3923.25% from $856.0 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Common Equity registered a high of $920.2 million during Q3 2025, and its lowest value of $178.7 million during Q1 2021.
  • In the last 5 years, Catalyst Pharmaceuticals' Common Equity had a median value of $348.5 million in 2023 and averaged $441.0 million.
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Common Equity soared by 2195.37% in 2021, and later soared by 8962.7% in 2024.
  • Catalyst Pharmaceuticals' Common Equity (Quarter) stood at $206.8 million in 2021, then skyrocketed by 45.25% to $300.4 million in 2022, then grew by 29.11% to $387.9 million in 2023, then skyrocketed by 87.59% to $727.6 million in 2024, then rose by 26.47% to $920.2 million in 2025.
  • Its Common Equity stands at $920.2 million for Q3 2025, versus $856.0 million for Q2 2025 and $794.3 million for Q1 2025.